New study aims to uncover why biliary tree cancers behave differently
NCT ID NCT05179486
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study collects tissue and blood samples from 1,500 people with biliary tree cancers, plus healthy volunteers, to look for genetic changes and risk factors. Researchers hope to build models that predict how the cancer develops and responds to treatment. The goal is to better understand the disease, not to test a new therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better understand what causes biliary tree cancers and why some people respond differently to treatments.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly help participants. It may take years to produce useful results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Can a new drug ST316 shrink Hard-to-Treat tumors?